213 related articles for article (PubMed ID: 19698110)
1. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.
Al Sarakbi W; Sasi W; Jiang WG; Roberts T; Newbold RF; Mokbel K
BMC Cancer; 2009 Aug; 9():290. PubMed ID: 19698110
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis.
Newbold RF; Mokbel K
Anticancer Res; 2010 Sep; 30(9):3309-11. PubMed ID: 20944102
[TBL] [Abstract][Full Text] [Related]
3. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a tumour suppressive function of APRG1 in breast cancer.
Leris AC; Roberts TR; Jiang WG; Newbold RF; Mokbel K
Breast Cancer Res Treat; 2005 Sep; 93(2):97-100. PubMed ID: 16187228
[TBL] [Abstract][Full Text] [Related]
5. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
6. mRNA Expression of
Gera R; Mokbel L; Jiang WG; Mokbel K
Cancer Genomics Proteomics; 2018; 15(6):447-452. PubMed ID: 30343278
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a tumour suppressor function for DLEC1 in human breast cancer.
Al Sarakbi W; Reefy S; Jiang WG; Roberts T; Newbold RF; Mokbel K
Anticancer Res; 2010 Apr; 30(4):1079-82. PubMed ID: 20530412
[TBL] [Abstract][Full Text] [Related]
8. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes.
Xie P; Tian C; An L; Nie J; Lu K; Xing G; Zhang L; He F
Cell Signal; 2008 Sep; 20(9):1671-8. PubMed ID: 18585004
[TBL] [Abstract][Full Text] [Related]
10. High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.
Salhab M; Patani N; Jiang W; Mokbel K
Breast Cancer; 2012 Apr; 19(2):153-60. PubMed ID: 20972741
[TBL] [Abstract][Full Text] [Related]
11. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
12. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
[TBL] [Abstract][Full Text] [Related]
13. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.
Sasi W; Jiang WG; Sharma A; Mokbel K
BMC Cancer; 2010 Apr; 10():178. PubMed ID: 20433750
[TBL] [Abstract][Full Text] [Related]
14. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion.
Chen Z; Raghoonundun C; Chen W; Zhang Y; Tang W; Fan X; Shi X
Biochem Biophys Res Commun; 2018 Apr; 498(3):579-585. PubMed ID: 29522714
[TBL] [Abstract][Full Text] [Related]
15. The mRNA expression of DAP1 in human breast cancer: correlation with clinicopathological parameters.
Wazir U; Jiang WG; Sharma AK; Mokbel K
Cancer Genomics Proteomics; 2012; 9(4):199-201. PubMed ID: 22798505
[TBL] [Abstract][Full Text] [Related]
16. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
17. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
18. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
19. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
20. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
